Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...
Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab extended PFS and OS. A higher percentage of patients assigned the ...
In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab ...
An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway Results from the IDeate-Lung01 ...
The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback